Cullinan Therapeutics Inc
Company Profile
Business description
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
Contact
One Main Street
Suite 1350
CambridgeMA02142
USAT: +1 617 410-4650
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
109
Stocks News & Analysis
stocks
Apple earnings: A smooth transition despite continued memory and supply headwinds
stocks
Two new ASX names added to our Global Best Stock Ideas
stocks
Big four bank holds up in weakening economic conditions
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,972.40 | 36.50 | -0.41% |
| CAC 40 | 8,020.31 | 27.38 | -0.34% |
| DAX 40 | 25,864.62 | 116.47 | -0.45% |
| Dow JONES (US) | 51,786.72 | 197.26 | -0.38% |
| FTSE 100 | 10,638.43 | 122.90 | -1.14% |
| HKSE | 23,428.87 | 97.10 | -0.41% |
| NASDAQ | 25,372.01 | 207.65 | 0.83% |
| Nikkei 225 | 61,258.23 | 1,823.63 | -2.89% |
| NZX 50 Index | 13,767.87 | 47.61 | 0.35% |
| S&P 500 | 7,568.92 | 27.52 | 0.36% |
| S&P/ASX 200 | 8,850.70 | 36.10 | -0.41% |
| SSE Composite Index | 3,606.67 | 1.43 | -0.04% |